Anti cytokine therapy of secondarily-progressing multiple sclerosis (ms)

Е. I. Gusev; Т. L. Demina; А. N. Boiko; А. V. Buglak; I. А. Belyaeva; N. F. Smirnova; Т. G. Alekseeva; М. V. Pashchenkov; В. Skurkovich; D. Kelly; S. V. Skurkovic

doi:10.17816/nb79894

Neurology Bulletin ›› 1997, Vol. XXIX ›› Issue (1-2) : 55 -58. DOI: 10.17816/nb79894

Articles

research-article

Anti cytokine therapy of secondarily-progressing multiple sclerosis (ms)

Author information +

History +

PDF

Abstract

For treating active forms of secondarily-progressing multiple sclerosis a preliminary clinical trial was performed by two courses: antibody-to-cytokine course (γINT, αINT and TNFα) and cyclosporin А-course (sandimmun). Data of preliminary test of antibodies to cytokines evidence to possibility of performing further clinical trials "antibodies to γINT and to TNFα (to a lesser degree)" during active forms of progressive MS. Were obtained the results, evidencing to a possible use of sandimmun in constantly progressive forms of secondarily progressing disease, when favourable clinical effect coincided with supression of cytokine IL-2 production and lowering of activeness of immunocytes.

Keywords

Neurological archive of Bekhterev

Cite this article

Download citation ▾

Е. I. Gusev, Т. L. Demina, А. N. Boiko, А. V. Buglak, I. А. Belyaeva, N. F. Smirnova, Т. G. Alekseeva, М. V. Pashchenkov, В. Skurkovich, D. Kelly, S. V. Skurkovic. Anti cytokine therapy of secondarily-progressing multiple sclerosis (ms). Neurology Bulletin, 1997, XXIX(1-2): 55-58 DOI:10.17816/nb79894

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Гусев Е.И., Демина Т.Л., Бойко А.Н., Татаринова М.Ю. // Журн. невропатол. и психиатр.—1992.—№ 2.—С. 14—18.

[2]	Arnason B.G.W., Reder А.Т. // Clin. Neuropharmacol.— 1994—Vol.17 .—P.495—547.

[3]	Goodkin D.E. // West J. Med.—1994.—Vol.161.— P.292—298.

[4]	Gusev E.I., Demina T.L., Boiko A.N., Pinegin B.V. // J. Neurol.—1994.—Vol.241—P.500—510.

[5]	Gusev E.I., Demina T.L., Boiko A.N., Favorova 0.0. In: Milonas I (ed). Proceedings of the 10th ECTRIMS Congress.—University Studio Press, Thessaloniki, Greece, 1995.—P.201—203.

[6]	IFNB Multiple Sclerosis Study Group, the University of British Columbia, MS/MRI Analisis Group. Interferon betalb in the treatment of MS: final outcome of the randomized controlled trial.—Neurology.—1995.—Vol.45.—P.1277—1285.

[7]	Jacobs L., Cookfair D.L., Rudick R.A. et al. // Ann. Neurol.—1996.—Vol.39—P.285—294.

[8]	Kahan B.D. // J. Med.—1989.—Vol.321.—P.1725—1739.

[9]	Khoury S.J., Weiner H.L., Hafler D.A. In: Cook S (ed). Handbook of multiple sclerosis.—N.-Y., 1990.—P.129—150.

[10]	Kirk J. // J.Neuroimmunol.—1991.—Vol.32.—P.87—94.

[11]	McFarlin D.E. // Ann. Allergy.—1990.—Vol.64.— P.433—444.

[12]	Multiple Sclerosis Study Group. Efficacy and toxicity of cyclosporine in chronic progressive multiple sclerosis: a randomized, double-blinded, placebo-controlled clinical trial.—Ann. Neurol.—1990.—Vol.27.—P.591—605.

[13]	Poser C.M., Paty D.W., Scheinberg L. et al. // Ann. Neurol.— Vol. 13.—P.227—231.

[14]	Ruddle N.H., Beyman C.M., McGrath M.L. et al. // J. Exp. Med. —1990.—Vol. 172.—P. 1193—1200.

[15]	Selmaj K., Rain C.S. // Ann. Neurol.—1991—Vol.30.- P.694—700.

[16]	The Canadian Cooperative Multiple Sclerosis Study Group. The Canadian cooperative trial of cyclophosphamide and plasma exchange in progressive multiple sclerosis // Lancet.— 1991.—Vol.337.—P.441—446.

[17]	Weiner H.L., Ellison G.W. // Arch. Neurol.—1983.— Vol.40.—P.704—710.

[18]	Whitaker LN. // Ann. Neurol.—1994.—Vol.36.- P.103—107.

RIGHTS & PERMISSIONS

Gusev Е.I., Demina Т.L., Boiko А.N., Buglak А.V., Belyaeva I.А., Smirnova N.F., Alekseeva Т.G., Pashchenkov М.V., Skurkovich В., Kelly D., Skurkovic S.V.